0001209191-19-057610.txt : 20191121 0001209191-19-057610.hdr.sgml : 20191121 20191121162110 ACCESSION NUMBER: 0001209191-19-057610 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191119 FILED AS OF DATE: 20191121 DATE AS OF CHANGE: 20191121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEIDEN JEFFREY M CENTRAL INDEX KEY: 0001242825 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 191237634 MAIL ADDRESS: STREET 1: 40 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-11-19 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2019-11-19 4 M 0 64032 109.14 A 170378 D Common Stock 2019-11-19 4 M 0 32502 131.89 A 202880 D Common Stock 2019-11-19 4 S 0 62886 210.41 D 139994 D Common Stock 2019-11-19 4 S 0 23033 211.43 D 116961 D Common Stock 2019-11-19 4 S 0 10615 212.75 D 106346 D Common Stock 440 I 401(k) Stock Option (Right to Buy) 109.14 2019-11-19 4 M 0 64032 0.00 D 2025-02-02 Common Stock 64032 0 D Stock Option (Right to Buy) 131.89 2019-11-19 4 M 0 32502 0.00 D 2025-07-20 Common Stock 32502 0 D Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $210.41 (range $210.06 to $210.83). Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $211.43 (range $211.08 to $211.97). Open market sales reported on this line occurred at a weighted average price of $212.75 (range $212.30 to $212.97). Fully vested. /s/ Omar White, Attorney-in-Fact 2019-11-21